Evidence map›Paper›PMID 11157685›Full record

Trial reportCirculation2001

Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study.

D J Freeman, J Norrie, N Sattar, R D Neely, S M Cobbe, I Ford, C Isles, A R Lorimer, P W Macfarlane, J H McKillop and 3 more

2 registry-linked trialsOpen access · bronzeAbstract readClinical TrialRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in Circulation, 2001. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 193 papers, 10 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
193citing papers in PubMed, 10 pooled it
69.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02470455 completedstarted 2011, after this paper: background citation

Effect of Atorvastatin on Glycemic Control in Prediabetic Patients

Ran2011Enrolled75Registered outcomes4Posted comparisons0ConditionsPrediabetic StateArmsAtorvastatin
PMID 18191683PMID 14514569PMID 20167359PMID 17317382PMID 12573493PMID 15031036other papers from this trial
Open the trial in the graph
NCT02754739 phase4completedstarted 2014, after this paper: background citation

Effect of Pravastatin in the Subjects With Prediabetes or Early Diabetes

Ran2014Enrolled44Registered outcomes10Posted comparisons0ConditionsDiabetes Mellitus, Prediabetic StateArmsNutritional education only, Placebo (for Pravastatin), pravastatin
PMID 15589072PMID 20167359PMID 19794004PMID 10480510PMID 18957530PMID 10902785PMID 6023769other papers from this trial
Open the trial in the graph
3 · Its place in the literature

Who cites it

193 citing papers in PubMed, 10 syntheses or guidelines pooled it, 845 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Statins impair glucose uptake in tumor cells.Neoplasia (New York, N.Y.) · 2012
    Trial
  19. Trial
  20. Trial

133 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 1 country.

D J FreemanDepartment of Biological Sciences, University of Durham, Durham, UK.
J Norrie
N Sattar
R D Neely
S M Cobbe
I Ford
C Isles
A R Lorimer
P W Macfarlane
J H McKillop
C J Packard
J Shepherd
A Gaw
Glasgow Royal Infirmary · GBUniversity of Glasgow · GBDumfries and Galloway Royal Infirmary · GBUniversity Hospital of North Durham · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundWe examined the development of new diabetes mellitus in men aged 45 to 64 years during the West of Scotland Coronary Prevention Study. METHODS AND

resultsOur definition of diabetes mellitus was based on the American Diabetic Association threshold of a blood glucose level of >/=7.0 mmol/L. Subjects who self-reported diabetes at baseline or had a baseline glucose level of >/=7.0 mmol/L were excluded from the analyses. A total of 5974 of the 6595 randomized subjects were included in the analysis, and 139 subjects became diabetic during the study. The baseline predictors of the transition from normal glucose control to diabetes were studied. In the univariate model, body mass index, log triglyceride, log white blood cell count, systolic blood pressure, total and HDL cholesterol, glucose, and randomized treatment assignment to pravastatin were significant predictors. In a multivariate model, body mass index, log triglyceride, glucose, and pravastatin therapy were retained as predictors of diabetes in this cohort.

conclusionsWe concluded that the assignment to pravastatin therapy resulted in a 30% reduction (P:=0.042) in the hazard of becoming diabetic. By lowering plasma triglyceride levels, pravastatin therapy may favorably influence the development of diabetes, but other explanations, such as the anti-inflammatory properties of this drug in combination with its endothelial effects, cannot be excluded with these analyses.

Indexed as

Anticholesteremic AgentsBlood GlucoseBody Mass IndexCohort StudiesCoronary DiseaseDiabetes MellitusHumansMaleMiddle AgedMultivariate AnalysisPravastatinProspective StudiesRisk FactorsTriglyceridesAnticholesteremic AgentsBlood GlucosePravastatinTriglycerides

Identifiers

PMID11157685
OpenAlexW2061489988

What Socratic holds

Texttitle and abstract
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.